Newsletter | July 12, 2025

07.12.25 -- Life Science Leader Best Of June

JUNE'S BEST FEATURED EDITORIAL

Promoting A Newly Approved Indication Against Established Competitors

By Ben Comer, Chief Editor, Life Science Leader

In a follow up to his recent appearance on the Business of Biotech, Tolga Tanguler explains how Alnylam is positioning Amvuttra's new ATTR-CM indication approval against competitors in the category.

JUNE'S BEST INDUSTRY INSIGHTS

What Is Direct-To-Patient Clinical Trial Recruitment?

What is the direct-to-patient (DtP) recruitment, and how can sponsors and organizers leverage this approach to boost patient recruitment and achieve clinical trial goals?

Europe's Platform For Driving More Flexible Clinical Trials: It's Time To Use It

Despite recent setbacks, Europe possesses inherent strengths in clinical research, and a concerted effort is needed to transform its potential into a thriving and competitive environment.

Customized Release Through Dispersed Dosage Formats

Typically, dosage format is based on the target product profile: how the developer envisions the product best addressing a clinical indication by maintaining population-wide efficacy.